Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.47 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 2/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4329928 | 0.85 | LDHA (0.47) | ACMSDLDHAMDM2CYP1A2SLC7A5 | |
| SCHEMBL6746251 | 0.84 | SLC7A5 (0.62) | TDP1SLC7A5GRIA2 | |
| SCHEMBL4328902 | 0.82 | CYP4F2 (0.56) | CYP4F2CYP4A11LDHASLC7A5FOLH1 | |
| SCHEMBL239199 | 0.79 | TDP1 (0.65) | TDP1CYP4F2CYP4A11ACMSDKMT2A | |
| SCHEMBL11529979 | 0.79 | LDHA (0.46) | LDHAMDM2CYP1A2SLC7A5FOLH1 | |
| SCHEMBL11153758 | 0.78 | PPARA (0.56) | — | |
| SCHEMBL3922659 | 0.77 | NPC1 (0.53) | TDP1CYP4F2CYP4A11ACMSDKMT2A | |
| SCHEMBL5968748 | 0.77 | AKR1B1 (0.56) | TDP1CYP4F2CYP4A11ACMSDCYP1A2 | |
| SCHEMBL491093 | 0.77 | GRIA2 (0.58) | LDHAMDM2CYP1A2GRIA2 | |
| SCHEMBL9338131 | 0.77 | TDP1 (0.46) | TDP1CYP4F2CYP4A11ACMSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | TDP1 4437/4885CYP4F2 792/4885CYP4A11 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.